TELA Bio, Inc. develops and commercializes soft-tissue reconstruction solutions for surgeons, with a focus on products designed to preserve and restore patient anatomy while limiting long-term exposure to permanent synthetic materials. Its OviTex portfolio includes configurations used in hernia repair and abdominal wall reconstruction, including ventral, inguinal and hiatal procedures.
Company news commonly covers quarterly and annual results, revenue guidance, commercial execution, product portfolio updates, credit and capital actions, board and leadership changes, and equity compensation grants made under Nasdaq inducement-grant rules.
TELA Bio (NASDAQ: TELA) announces positive findings from six studies demonstrating the effectiveness of OviTex Reinforced Tissue Matrix in hernia repair and abdominal wall reconstruction. Published in 2022, these studies encompass data from 280 patients, showcasing lower complication and recurrence rates compared to traditional mesh products. The research highlights OviTex as a superior alternative in various applications, aligning with the growing demand for safer surgical options. With over two million hernia repairs expected in the US and Europe this year, TELA aims to enhance patient outcomes through innovative soft-tissue solutions.
TELA Bio, Inc. (NASDAQ: TELA), a company focused on innovative soft-tissue reconstruction solutions, will report its fourth quarter and full year 2022 financial results on March 21, 2023. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide corporate updates. TELA Bio aims to optimize clinical outcomes by prioritizing the preservation of patients' anatomy, providing economically effective solutions while minimizing long-term exposure to synthetic materials. Investors and interested parties can register for the call in advance or access a replay on TELA's website.
TELA Bio (NASDAQ: TELA), a commercial-stage medical technology company, announced the approval of restricted stock units covering 2,600 shares for three newly-hired employees, effective February 21, 2023. This grant was made under the Nasdaq Rule 5635(c)(4) inducement grant exception, as part of the employees' compensation and to encourage their acceptance of employment with TELA Bio. The restricted stock units will vest annually over four years, contingent on the employees' continued service. TELA Bio aims to enhance clinical outcomes through innovative soft-tissue reconstruction solutions, prioritizing the use of the patient's own anatomy.
TELA Bio, Inc. (NASDAQ: TELA) has launched two new larger configurations of its OviTex LPR device, aimed at improving hernia repair procedures. The new sizes, 15 x 20 cm and 15 x 25 cm, cater specifically to ventral and incisional hernias and enhance minimally invasive surgery applications. Since its initial launch in 2018, OviTex has been well-adopted among surgeons, with 40% of cases performed robotically and 20% laparoscopically in the last quarter. The device utilizes a unique ovine-derived tissue matrix for functional tissue remodeling, reinforcing TELA's commitment to innovating soft-tissue reconstruction solutions.
On February 14, 2023, TELA Bio, a commercial-stage medical technology company (NASDAQ: TELA), announced a significant three-year agreement with a national group purchasing organization (GPO) for its biosynthetic products. This contract, effective until January 1, 2026, aims to enhance accessibility to TELA's OviTex Reinforced Tissue Matrix for GPO members, promising considerable cost savings and clinical benefits. CEO Antony Koblish expressed optimism about this partnership, emphasizing the company's commitment to delivering high-quality solutions in soft tissue repair. This agreement presents a potential growth opportunity by broadening market access.
TELA Bio has announced the approval of stock options and restricted stock units for 10 new employees, totaling 4,200 stock options and 7,250 restricted stock units. The options have an exercise price of $11.80 per share, based on the stock’s closing price on the grant date of January 18, 2023. The options are set to vest over four years, while the restricted units will vest annually over the same period. These grants are part of the employment compensation package and aim to attract talent as TELA Bio continues its focus on innovative medical technologies for soft-tissue reconstruction.
TELA Bio has launched the NIVIS Fibrillar Collagen Pack, enhancing its product portfolio aimed at optimizing soft tissue preservation and restoration. The product, made of Type I and III bovine collagen, is designed for managing moderately to heavily exudating wounds and controlling minor bleeding. Dr. Michael Sawyer noted its effective handling in high-risk surgical wound management. This launch follows TELA's exclusive partnership with Collagen Matrix, Inc. and aligns with its mission to provide advanced soft-tissue reconstruction solutions.
TELA Bio is set to present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 am ET. The company focuses on innovative soft-tissue reconstruction technologies that enhance clinical outcomes by prioritizing the preservation of the patient's anatomy. Interested individuals can access the live and archived webcast through ir.telabio.com. TELA Bio is committed to offering economically effective solutions that utilize the patient's natural healing response, minimizing reliance on synthetic materials.
TELA Bio, Inc. (NASDAQ: TELA) announced the approval of stock options totaling 15,450 shares for 8 new hires as part of their employment compensation on December 7, 2022. The options, granted under Nasdaq Rule 5635(c)(4), have an exercise price of $9.58 per share and a ten-year term, vesting over four years. This strategy emphasizes TELA Bio's commitment to attract talent as it focuses on innovative soft-tissue reconstruction technologies to enhance clinical outcomes.
TELA Bio, a commercial-stage medical technology company, reported a revenue of $11.2 million for Q3 2022, marking a 46% increase year-over-year. The company highlighted rising demand for its OviTex products, achieving 29% and 108% revenue growth for OviTex and OviTex PRS, respectively. They completed a public offering that netted $34.4 million. Despite increased operating expenses totaling $16.8 million, TELA Bio anticipates steady recovery in procedure volumes post-COVID-19 and projects full-year revenue between $42 million and $45 million, representing 43%-53% growth over 2021.